Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 2,901–3,000 of 3,116
Beyond efficacy: health inequities limiting access to semaglutide for obesity management
Islam, K., & Hassan, M. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag129
Rashid, M., Lee, E. L., Veettil, S. K., Dhippayom, T., Cheng, A. Y. Y., SIMONETTI, J. S., & Chaiyakunapruk, N. (2026) · Obesity Reviews · doi:10.1111/obr.70198
Matson, R., Venkatakrishnan, A., Murugadoss, K., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag042 · Cited by 1
Weekly Journal Scan: a novel RNA-based approach to the treatment of hypertriglyceridaemia
Galiuto, L., & Volpe, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae351 · Cited by 1
Li, M. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1926629
“SELECT has already influenced guidance for secondary prevention in obesity without diabetes, whereas FLOW has strengthened the kidney rationale for semaglutide beyond earlier albuminuria-based evidence.”
InfluentialFleming, T. R., Carroll, K. J., Wittes, J. T., et al. (2026) · Statistics in Medicine · doi:10.1002/sim.70622
Self-citationStörungen von Ernährung und Stoffwechsel
Parhofer, K. G., & Hauner, H. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21184-3.00008-9
Zapp, C., Downer, D. M., Levine, A., Parker, N., Zapp, M., Downer, D. M., & Levine, L. (2026) · Cureus · doi:10.7759/cureus.102921 · Cited by 2
“Other benefits of GLP-1RAs include improvements in cholesterol profiles, steatohepatitis, neurodegenerative diseases, and sleep apnea [12-15].”
Actividad Física, Ejercicio y Salud: Retos Actuales y Desafíos Futuros
Jiménez‐Pavón, D. (2024) · Revista Andaluza de Medicina del Deporte · doi:10.33155/ramd.v17i1-2.1172 · Cited by 1
Expert Consensus on the Management of Obesity in Older Adults (2026 Edition)
Pan, Q., & Guo, L. (2026) · Aging Medicine · doi:10.1002/agm2.70105
“In addition, a study ( n = 8803; mean age, 61.6 years) showed that semaglutide 2.4 mg reduced MACE risk by 20% in patients with overweight or obesity and ASCVD, with similar cardiovascular benefits across age groups in subgroup analyses [75].”
InfluentialTomasiewicz, A., Zabierowski, J., Pachana, M., Kukuła, P., Piersiak, M., Sawczuk, H., Marschollek, J., & Ziomek, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.4067
Drogy, M. S., Minto, S. T., & Frishman, W. H. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001259 · Cited by 3
Jiang, C., Qiu, J., Wei, C., Zhou, E., Zhu, H., Huang, W., Zhou, T., & Hu, J. (2026) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70180
“…and tirzepatide have shown clinically meaningful weight-loss effects in adults with overweight or obesity [ 37, 38 ], and semaglutide has also been associated with reduced cardiovascular events among selected patients with overweight or obesity and established cardiovascular disease [ 39 ].”
Reges, O., Ahmad, W. A., Ramot, N., Battat, E., Greenland, P., Arbel, R., Sagy, Y. W., Lavie, G., & Diker, D. (2026) · Obesity Facts · doi:10.1159/000551805
“Obes Facts DOI: 10.1159/000551805 study, semaglutide 2.4 mg demonstrated reduction in the risk of MACE by 20% in people living with obesity [17].”
InfluentialOptimized Protocols to Extract Total Transcripts and Proteins from Lipid-Rich Tissues
de Azevedo, N., Lozano, A., Parsons, R. E., & Martin, T. C. (2026) · Methods and Protocols · doi:10.3390/mps9020065
Are Weight-loss Drugs the Next Treatment for Obstructive Sleep Apnea?
Burling, S. (2024) · Neurology Today · doi:10.1097/01.nt.0001028048.95871.c0
Yuan, J., Ji, T., Chen, R., Yuan, Y., & Ji, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1886093
“Similarly, semaglutide reduced major adverse cardiovascular events in the SELECT trial among adults with overweight or obesity and established cardiovascular disease (94).”
Ciancimino, G., Pecorella, F., Viscardi, S. M., Mantia, C. L., Caserta, A., Pennisi, G., & Petta, S. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.19
Андреевна, К. Е., Анатольевна, Г. А., Егоровна, С. Е., & Tukish, O. V. (2025) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2025-6-4-7-15
If GLP-1s are “longevity drugs,” the evidence bar must change—carefully
Jones, C. H., & Dolsten, M. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104707
Comprehensive Management Strategies for Cardiovascular–Kidney–Metabolic Syndrome
Ouatu, A., & Buliga-Finiș, O. N. (2025) · Springer eBooks · doi:10.1007/978-3-032-11445-7_18
Incretin polyagonists as an alternative to bariatric surgery to manage obesity
Manoj, R. J., Fernandez, C. J., Nair, S., & Pappachan, J. M. (2026) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v17.i1.118132
Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?
Ihle‐Hansen, H., Ihle-Hansen, H., Blauenfeldt, R. A., Dawson, J., Diederichsen, S. Z., & Hagberg, G. (2026) · Frontiers in Stroke · doi:10.3389/fstro.2026.1918465
“In the absence of T2DM, semaglutide has been shown to improve cardiovascular outcomes, including reductions in MACE (HR 0.80; 95% CI 0.72–0.90) in people who are overweight (Body Mass Index ≥ 27 kg/m 2 ) and have established CVD (Lincoff et al., 2023).”
InfluentialHass, D., Madsen, A. N., da Silva‐Buttkus, P., Kjølbye, A. L., Støy, S. H., Nøhr-Meldgaard, J., Sandahl, T. D., de Angelis, M. H., Jørgensen, R., Rohm, M., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.041
GLP-1-Rezeptor-Agonisten bei Patienten mit Herzinsuffizienz?
Schröder, S. C., Laufs, U., & Nitschmann, S. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01763-7
ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES
Wielogórska, A., Stasiak, O., Kowalik, F., & Deczkowska, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.5972
How We Monitor Cardiac Health in Breast Cancer Survivors
Clasen, S. C., & Miller, M. E. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00757
Contemporary Medical Management of Carotid Artery Stenosis
Salameh, M., & Ratchford, E. V. (2026) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2026.01.001 · Cited by 1
Feraco, A., Camajani, E., Muscogiuri, G., Barrea, L., Colao, A., & Caprio, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00695-7 · Cited by 2
Semaglutid bei Herzinsuffizienz mit erhaltener Ejektionsfraktion (HFpEF)
Dürschmied, D., Weidner, K., & Nitschmann, S. (2025) · Die Innere Medizin · doi:10.1007/s00108-024-01844-7
Li, A., Ma, Y., Chen, Z., Lu, Q., Liu, C., Zhou, P., Liang, Q., Tao, Y., Chen, M., Chen, Z., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1817298
Integrating lifespan biology into obesity science
Suliman, S. G. I., & Sargent, J. L. (2026) · Metabologia · doi:10.1007/s44357-026-00005-7
Stéatohépatite associée à un dysfonctionnement métabolique (MASH) : prise en charge
Farrugia, M. A., Gual, P., & Anty, R. (2026) · EMC - Hépatologie · doi:10.1016/s1155-1976(25)50657-5
McGovern, A., Cinfio, F. N., & Luo, R. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01647-8
Research Progress of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Heart Failure
胡, 明. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1571991
SEMAGLUTIDE FOR WEIGHT REDUCTION: A COMPARATIVE ANALYSIS WITH OTHER PHARMACOLOGICAL TREATMENTS
Handzel, M., Czerniewska, J., Jurkowska, K., Madrzak, J., Endler, O., Dybicz, M., Ciastoń, M., Filuk, M., Fidelus, J., & Dutkiewicz, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5726
Grewal, U. S., Ear, P. H., Sonbol, M. B., Bellizzi, A. M., Hofland, J., Crona, J., Dillon, J. S., Chan, J. A., Howe, J. R., Strosberg, J., et al. (2026) · Cancer · doi:10.1002/cncr.70586
“4 9 As indications continue to expand and newer, more potent agents emerge, use of these therapies is expected to increase further.”
Beyond Body Mass Index: Body Roundness Index, Inflammation, and MortalityPreprint
Lin, D. S., Chua, S., & Lee, J. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5391653
Zavaleta‐Monestel, E., Arguedas‐Chacón, S., Mora-Jiménez, J., Villalobos-Madríz, J. A., Enríquez-Gutiérrez, B., & Tencio-Morales, K. (2026) · Endocrines · doi:10.3390/endocrines7030044
“This concordance between VigiBase and pivotal trial data reinforces the external validity of our descriptive findings, although the focus of this study remains the psychiatric domain [19,20].”
Velasco, A., Ramos, I. P., Alonso, P. R., Sanz, C. D., Tello, R., & Solís, J. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502455
GLP-1 and Nutrient Stimulated Hormone Targets: Beyond Weight Loss
Ryan, D. H. (2026) · Dermatologic Surgery · doi:10.1097/dss.0000000000005113
Self-citationGiamundo, D. M., Andò, G., Mamas, M. A., Pathak, A., Rosa, S. D., Bernardi, M., Figliozzi, S., Alasnag, M. A., Atar, D., Asher, E., et al. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13080393
“SELECT demonstrated that semaglutide reduced major cardiovascular events in patients with established cardiovascular disease and overweight or obesity without diabetes [69].”
Elkin, J., Schilling, C. G., Thuraisingam, S., Hi, M. W., Sumithran, P., Choong, P., Dowsey, M. M., & Shadbolt, C. (2026) · The Medical Journal of Australia · doi:10.5694/mja2.70253
“Established cardiovascular disease was defined in the clinical trial used to support this indication as having had a prior myocardial infarction, having had a prior stroke or having symptomatic peripheral arterial disease [7].”
InfluentialMapelli, M., Carugo, S., Salvioni, E., & Agostoni, P. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106823
Trends in GLP ‐1 Receptor Agonist Prescribing Without Documented Indications
Kim, C., Choi, K., Krumholz, H. M., & Lu, Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71153
Butler, J., Jamil, A., Cherney, D. Z. I., Jafar, T. H., Testani, J. M., & Khan, M. S. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag426 · Cited by 1
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.69 · Cited by 1
Tangirala, S., Isaac, S., Gehad, Y., Roquefort, F., Gabrieli, P., Leong, A., Mercader, J. M., Sevilla-González, M. D. R., Baldini, F., Miller, G. W., et al. (2025) · medRxiv · doi:10.1101/2025.09.26.25336579
Zhao, Z., & Hu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14091884
“…MASH-related trials all suggest that while incretin-based drugs provide benefits in weight reduction and metabolic parameters, attention should also be paid to gastrointestinal tolerability, discontinuation rates, long-term adherence, and the risk of gallbladder or biliary tract disease [16,71,72].”
Obesity Management and Cardiovascular Risk Reduction: from Tradition to Innovation
Costa, T. A., Harrington, J., Nelson, A. J., Pandey, A., Neeland, I. J., Lee, M. M. Y., Kang, Y. M., & McGuire, D. K. (2026) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-026-01138-1
Phillips, C. L., Chapman, J. L., & Yee, B. J. (2024) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2024.102020
Karanxha, J., Guni, M., Xhabija, N., Dede, M., Mone, I., & Prifti, E. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134773
Jeske, P., Bobkiewicz, A., Roleder, J., Paszkowski, J., Krokowicz, Ł., & Szmyt, K. (2026) · Research Square · doi:10.21203/rs.3.rs-9910074/v1
Torre, E., Matteo, S. D., Martinotti, C., Bruno, G. M., Cabrino, A., Fogliati, E., Giusti, A., Barbieri, M., Bottaro, L. C., & Colombo, G. L. (2026) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s585328
“9,10,14 Specifically, the STEP 1 trial provided a mean reduction in body weight of −14.9% in the semaglutide 2.4 mg group compared with −2.4% for placebo (95% confidence interval [CI], −13.4 to −11.5; P<0.001) at 68 weeks.”
InfluentialBelančić, A., Majanović, S. K., Skroče, K., Ciudin, A., & Borovac, J. A. (2026) · Medicina · doi:10.3390/medicina62081446
Does One Size Fit All? – Refining Parenteral Anticoagulant Therapy According to Body Weight
Furtado, R. H. D. M. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250251i
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications
Chao, A. M., Asante, R., Sersah, M. E., Jahangir, U. A., Peary, A., & Kudaya, D. Q. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70162
Peary, A., Vaidya, N., Jakicic, J., & Chao, A. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01426-y · Cited by 1
“In addition, these medications have demonstrated cardiometabolic benefits, including improved glycemic control, lower blood pressure, and reduction in major adverse cardiovascular events [32, 33].”
Johansson, E., Wilding, J. P. H., Upadhyay, N., van Hest, N., Kirk, M., Spaepen, E., Zimner‐Rapuch, S., Annemans, L., & Bays, H. E. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2646078 · Cited by 1
The Skinny on the Use of GLP‐1 Receptor Agonists in Peripheral Artery Disease
Beckman, J. A., & Annex, B. H. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.052332
Dhingra, N. K., & Verma, S. (2026) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2026.04.017
EFFECTIVENESS OF SEMAGLUTIDE IN OBESITY TREATMENT AND THE ROLE OF LIFESTYLE INTERVENTIONS
Bracichowicz, F., Winogrodzki, I., Kowalczyk, P., Paszkiewicz, H., Nowak, K., Gęsińska, A., Stryczek-Schlusche, A., Trzciński, B., Gugała, O., & Furczyńska, A. M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3931
Disparities in access to pharmacotherapies for weight loss and cardiovascular prevention
Duell, P. B., & Maki, K. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.08.001
Szerenos, N., Woroniecka, N., Trocka, D., Kozłowska, A., Przybysz, K., Stadnik, L., Zienkiewicz, N., Rachoń, J., Dzwonkowska, A., & Dzwonkowski, J. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6150
Hailu, K. T., Abriha, F. N., Duguma, Y. M., Haddad, R. R., Liyew, T., & Kasagga, A. (2026) · Cureus · doi:10.7759/cureus.110657 · Cited by 2
Cardiac GLP1R gene Expression: A Cross-Species Single-Cell Transcriptomic Analysis
(2026) · doi:10.64898/2026.01.18.700176
“…direct cardiac GLP1R signaling is limited to discrete receptor-positive populations and support the interpretation that indirect systemic mechanisms (cardiometabolic, vascular, renal, and anti-inflammatory effects) contribute substantially to the clinically observed cardioprotection 6,36,39,40 .”
Guglielmi, V., Musumeci, G., Galeone, C., Mariani, P., Baratta, R., Bellini, R., Cameli, M., Castaldini, N., Cesaro, A., Cosentino, N., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03010-2
Ganjre, S., Borah, L., & Khardenavis, A. (2026) · Cureus · doi:10.7759/cureus.117270
2026 ESC Guidelines on cardiac rehabilitation
Bäck, M., Wilhelm, M., Marcin, T., Machado, F. V. C., Sandberg, A., Buccheri, S., Conde, A. C., Czapla, M., Rosa, S. D., Gibson, I., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag417 · Cited by 3
Bone marrow rewired: Trained immunity and clonal hematopoiesis in metabolic disease
Chronopoulos, J., Hajishengallis, G., & Chavakis, T. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156603 · Cited by 4
A gyógyszer-repozicionálás és klinikai diabetológiai vonatkozásai
Pokoly, B., & Somogyi, A. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33177
Kow, C. S., Thiruchelvam, K., Hasan, S. S., & Zaihan, A. F. (2026) · Proceedings of Singapore Healthcare · doi:10.1177/20101058261424018
Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes
Chuan, F., Gao, Y., & Zhou, B. (2026) · New England Journal of Medicine · doi:10.1056/nejmc2600572
Mesawich, J., Threatt, T. B., & Mercer, D. (2025) · JAPhA Practice Innovations · doi:10.1016/j.japhpi.2025.100083 · Cited by 1
Grenet, G., Eskandari, R., Ko, J., Adams, S. P., Salzwedel, D. M., Heran, B. S., Ambasta, A., Bassett, K., & Thompson, W. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-006225
Zeng, B., Hsu, C.-W., Hung, C., Yang, W.-C., Stubbs, B., Chen, Y.-W., Lei, W.-T., Chen, J.-J., Chen, T., Hsu, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104026
Explanation of JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure (2)
Sezai, A., Tanaka, M., Kitano, D., & Okumura, Y. (2025) · Journal of Nihon University Medical Association · doi:10.4264/numa.84.6_245
Chronic coronary syndromes: Latest ESC recommendations and current insights from the literature
Mafrica, D., Franculli, G., Sarto, G., Esposito, A., Sudan, S., Biondi-Zoccai, G., Bernardi, M., & Sabouret, P. F. (2026) · Heart Vessels and Transplantation · doi:10.24969/hvt.2026.638
Badgandi, M., Srinath, A., Mandora, V., Kandar, D. K., Shukla, P., PUNATAR, D. H., Jain, V., Kumar, S., Girish, P., Budhwar, A., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_20_26
Medications for the Management of Obesity
Giruzzi, N. R. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch29
Miličević, T., Cvitković, I., Volčanšek, Š., Katsiki, N., Mikhailidis, D. P., Patoulias, D., & Muzurović, E. M. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2706660
“The trial achieved its primary objective by demonstrating a significant and superior reduction in MACE of 20% for over-weight and obese patients treated with semaglutide 2.4 mg compared with placebo (HR 0.80; 95% CI: 0.72–0.90, p < 0.001) [82].”
InfluentialRecent Updates on the Renoprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Choi, H. S., & Bae, E. H. (2025) · Korean Journal of Medicine · doi:10.3904/kjm.2025.100.2.61
Medeot, M. (2026) · Biomedicine Advances · doi:10.34172/bma.74
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Yin, J., Liu, Y., & Jia, W. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0417
Dong, H., Chen, Z., Xing, L., & Li, D. (2026) · Research Square · doi:10.21203/rs.3.rs-9794498/v1
Babenko, A. Y., & Игоревна, А. В. (2026) · Diabetes Mellitus · doi:10.14341/dm13474
Wilkins, F. L., Moore, W. S., Jackson, J. R., & McVay, M. A. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251392887
“16-20 While non-evidence-based practices for weight loss are commonly used, with 5% – 15% of individuals with obesity reporting use of these approaches for weight loss within the last year, 7,9,11 medications for obesity have historically been less widely used.”
Moiz, A., Reynier, P., Tsoukas, M. A., Yu, O. H., Peters, T. M., Eisenberg, M. J., & Filion, K. B. (2026) · Systematic Reviews · doi:10.1186/s13643-026-03153-6
“This study may also help identify areas where future trials are needed, particularly as GLP-1-based therapies continue to expand into new indications, including cardiovascular prevention [48], heart failure [49], and liver disease [50, 51].”
Eyadiel, L., & Modarressi, T. (2025) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2025.08.015
Mehetre, K. N., & Dawane, J. S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933913
“Cardiovascular outcome studies have also demonstrated reductions in cardiovascular events in patients with obesity and already have cardiovascular disease (94).”
Huang, Y., Yang, R., Wang, Y., Lu, X., Wei, L., Cheng, R., Cheng, J., Qiu, Y., Wang, S., Li, B., et al. (2026) · Portal hypertension & cirrhosis · doi:10.1002/poh2.70035 · Cited by 1
Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide
Oldenburg, L. I. K., Haugaard, S. P., Karlsson, T., Kegel, V., Parwez, M., Wiingaard, C., & Flint, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71096
“…benefits on major kidney outcomes, including a reduction in the rate of eGFR decline, major adverse cardiovascular events and all-cause mortality in participants with overweight/obesity and established cardiovascular disease without diabetes [10, 23], and T2D and CKD, respectively [12, 24].”
Recent Progression of Incretin-Based Obesity Treatment
Choi, D. (2024) · Korean Journal of Medicine · doi:10.3904/kjm.2024.99.2.78
GLP-1 therapies for obesity: mechanisms, outcomes, and regulatory challenges
Emos, D. D. O., González, J. D. J. M., Diani, L. M., Pinhel, M. A. D. S., Watanabe, L. M., Leca, A. V., Brandao, C. F. C., Nonino, C. B., & Noronha, N. Y. (2026) · Academia Drug Development and Pharmacotherapy · doi:10.20935/acaddrug8360
A sex-specific Mendelian randomization-phenome-wide association study of body mass index
Jiesisibieke, Z. L., Chan, I. I., Ng, J. C. M., & Schooling, C. M. (2025) · eLife · doi:10.1101/2024.09.12.24313524 · Cited by 1
Rethinking Lipid Burden and the Role of Non-LDL Biomarkers in Stroke Risk Stratification
Kelly, S. M., Schneider, J., Rosso, M., Ishida, K., Rostanski, S., & Katz, G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01449-5
“In fact, the SELECT trial results lends support to the idea that even patients without diabetes having signs of metabolic dysfunction indicated by TG: HDL ratio of ~ 3 could benefit from semaglutide therapy in addition lifestyle interventions [35].”
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Self-citationEisa, N., & Barood, O. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.03.003 · Cited by 1
Cardio-renal protection of MRAs in kidney-transplanted diabetic patients
Essawy, B. E., Safa, K., Dalbhi, S. A., & Chandraker, A. K. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108425 · Cited by 1
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
